Reuters: Regulatory News: Impax, GSK end Parkinson's disease partnership

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Impax, GSK end Parkinson's disease partnership Apr 29th 2013, 12:46 April 29 | Mon Apr 29, 2013 8:46am EDT April 29 (Reuters) - Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug. Impax shares fell 2 percent to $17.32 in premarket trade after closing at $17.62 on Friday on the Nasdaq. Under a deal, GlaxoSmithKline had the right to develop and market the drug, IPX066, outside the United States and Taiwan. Rights to the drug, which is known as Rytary in the United States, will transfer back to Impax at the end of July 2013. Impax did not disclose the financial impact of the deal termination, if any. It said it plans to find a partner or partners for markets outside the United States. Rytary is an extended-release capsule being developed for the symptomatic treatment of adult patients with idiopathic Parkinson's disease.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions